Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C3H3O3.Na |
| Molecular Weight | 110.0439 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(=O)C([O-])=O
InChI
InChIKey=DAEPDZWVDSPTHF-UHFFFAOYSA-M
InChI=1S/C3H4O3.Na/c1-2(4)3(5)6;/h1H3,(H,5,6);/q;+1/p-1
| Molecular Formula | Na |
| Molecular Weight | 22.98976928 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C3H3O3 |
| Molecular Weight | 87.0541 |
| Charge | -1 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
CTI-01 (ethyl pyruvate) is an investigational anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 was developed by Critical Therapeutics as a stable prodrug of pyruvate, a potent antioxidant, and a free radical scavenger. The drug showed an anti-inflammatory and tissue protection activity in animal models of pancreatitis, ischemia-reperfusion injury, sepsis, renal injury, and endotoxemia. CTI-01 was investigated in phase 2 clinical trials on patients undergoing cardiac surgery with cardiopulmonary bypass, but despite positive results in animal models, administration of EP does not appear to confer any benefit to cardiac surgical patients undergoing cardiopulmonary bypass. Besides clinical applications, ethyl pyruvate is long used as an additive to pharmaceutical preparations and foods, including candy, beverages, and baked goods. It is generally recognized as safe by the FDA.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: WP1290 |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Inactive ingredient | Rejuvesol Approved UseRejuvesol ® Solution is intended only to be used as an in vitro processing solution for the rejuvenation of a unit of RBC. Launch Date1997 |
|||
| Palliative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Kinetic resolution of chiral amines with omega-transaminase using an enzyme-membrane reactor. | 2001-05-05 |
|
| Chemo-enzymatic D-enantiomerization of DL-lactate. | 2001-04-05 |
|
| Functional complexes of mitochondria with Ca,MgATPases of myofibrils and sarcoplasmic reticulum in muscle cells. | 2001-04-02 |
|
| Glutamine supplementation promotes anaplerosis but not oxidative energy delivery in human skeletal muscle. | 2001-04 |
|
| Dichloroacetate improves cardiac efficiency after ischemia independent of changes in mitochondrial proton leak. | 2001-04 |
|
| Inhibitory effect of sorbitol on sugar metabolism of Streptococcus mutans in vitro and on acid production in dental plaque in vivo. | 2001-04 |
|
| Dysfunctional mitochondrial respiration in the wobbler mouse brain. | 2001-03-16 |
|
| Interdependent effects of inorganic phosphate and creatine phosphate on sarcoplasmic reticulum Ca2+ regulation in mechanically skinned rat skeletal muscle. | 2001-03-15 |
|
| Mitochondria control ampa/kainate receptor-induced cytoplasmic calcium deregulation in rat cerebellar granule cells. | 2001-03-15 |
|
| Snapshots of metabolic phenotypes. | 2001-03 |
|
| Regulation of skeletal muscle amino acid metabolism during exercise. | 2001-03 |
|
| Metabolic characteristics of muscles in the spiny lobster, Jasus edwardsii, and responses to emersion during simulated live transport. | 2001-03 |
|
| Active oligomeric states of pyruvate decarboxylase and their functional characterization. | 2001-03 |
|
| Enzymatic determination of acetylcarnitine for diagnostic applications. | 2001-03 |
|
| The first case of 4-hydroxybutyric aciduria in Japan. | 2001-03 |
|
| Glutamate regulates the viability of retinal cells in culture. | 2001-03 |
|
| Retrobiosynthetic nuclear magnetic resonance analysis of amino acid biosynthesis and intermediary metabolism. Metabolic flux in developing maize kernels. | 2001-03 |
|
| Congenital lactic acidosis: evaluation of the properties of the a199t natural variant of human pyruvate dehydrogenase e1alpha by in vitro mutation. | 2001-03 |
|
| Study of tricarboxylic acid cycle flux changes in human visual cortex during hemifield visual stimulation using (1)H-[(13)C] MRS and fMRI. | 2001-03 |
|
| Caveats when considering ketogenic diets for the treatment of pyruvate dehydrogenase complex deficiency. | 2001-03 |
|
| Molecular characterization, enzyme properties and transcriptional regulation of phosphoenolpyruvate carboxykinase and pyruvate kinase in a ruminal bacterium, Selenomonas ruminantium. | 2001-03 |
|
| Aerobic and anoxic biodegradation of benzoate: stability of biodegradative capability under endogenous conditions. | 2001-03 |
|
| Different sensitivity of rabbit heart and skeletal muscle to endotoxin-induced impairment of mitochondrial function. | 2001-03 |
|
| Formation of Fallopian tubal fluid: role of a neglected epithelium. | 2001-03 |
|
| Crystallization and initial X-ray diffraction analysis of human pyruvate dehydrogenase. | 2001-03 |
|
| IL-4 gene expression up-regulated by mercury in rat mast cells: a role of oxidant stress in IL-4 transcription. | 2001-03 |
|
| The use of biomarkers in Daphnia magna toxicity testing V. In vivo alterations in the carbohydrate metabolism of Daphnia magna exposed to sublethal concentrations of mercury and lindane. | 2001-03 |
|
| Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. | 2001-03 |
|
| Involvement of both phosphatidylinositol 3-kinase and p44/p42 mitogen-activated protein kinase pathways in the short-term regulation of pyruvate kinase L by insulin. | 2001-03 |
|
| Modulation of early [Ca2+]i rise in metabolically inhibited endothelial cells by xestospongin C. | 2001-03 |
|
| Multidrug resistance protein (MRP) activity in normal mature leukocytes and CD34-positive hematopoietic cells from peripheral blood. | 2001-02-02 |
|
| Lactic acidosis update for critical care clinicians. | 2001-02 |
|
| Beneficial effects of low-dose prostacyclin on cat intestinal perfusion during endotoxemia as evaluated with microdialysis and oxygen transport variables. | 2001-02 |
|
| Parasitism enhances the induction of glucogenesis by the insect, Manduca sexta L. | 2001-02 |
|
| The in vitro effects of isometamidium chloride (Samorin) on the piscine hemoflagellate Cryptobia salmositica (Kinetoplastida, Bodonina). | 2001-02 |
|
| Cloning of a pyruvate phosphate dikinase from Trypanosoma cruzi. | 2001-02 |
|
| Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC 58125, aggravates postischaemic cardiac dysfunction, independent of COX function. | 2001-02 |
|
| Lactate dehydrogenase from the northern krill Meganyctiphanes norvegica: comparison with LDH from the Antarctic krill Euphausia superba. | 2001-02 |
|
| Neuroprotective effects of MK-801 on L-2-chloropropionic acid-induced neurotoxicity. | 2001-02 |
|
| A compactly integrated flow cell with a chemiluminescent FIA system for determining lactate concentration in serum. | 2001-01-15 |
|
| 6-Phosphogluconate dehydrogenase deficiency in an Italian family. | 2001-01 |
|
| Intramitochondrial pyruvate attenuates hydrogen peroxide-induced apoptosis in bovine pulmonary artery endothelium. | 2001-01 |
|
| Reclassification of Desulfobacterium phenolicum as Desulfobacula phenolica comb. nov. and description of strain SaxT as Desulfotignum balticum gen. nov., sp. nov. | 2001-01 |
|
| Carboxydobrachium pacificum gen. nov., sp. nov., a new anaerobic, thermophilic, CO-utilizing marine bacterium from Okinawa Trough. | 2001-01 |
|
| Thioflavicoccus mobilis gen. nov., sp. nov., a novel purple sulfur bacterium with bacteriochlorophyll b. | 2001-01 |
|
| Metabolic alterations in cerebrospinal fluid from double hemorrhage model of dogs. | 2001-01 |
|
| Refinements in primary rumen epithelial cell incubation techniques. | 2001-01 |
|
| Severe canine hereditary hemolytic anemia treated by nonmyeloablative marrow transplantation. | 2001 |
|
| Rapid metabolic recovery following vigorous exercise in burrow-dwelling larval sea lampreys (Petromyzon marinus). | 2000-10-31 |
|
| Catabolic capacity of the muscles of shorebird chicks: maturation of function in relation to body size. | 2000-10-31 |
Sample Use Guides
In a clinical trial, 7,500 mg of ethyl pyruvate was administered intravenously starting after the induction of general anesthesia followed by 5 more doses of 7,500 mg administered every 6 hours. As an additive to pharmaceutical products and foods, ethyl pyruvate is administered orally
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:50:10 GMT 2025
by
admin
on
Mon Mar 31 17:50:10 GMT 2025
|
| Record UNII |
POD38AIF08
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
165602
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
||
|
DSLD |
3003 (Number of products:1)
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
113-24-6
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
PRIMARY | |||
|
DTXSID6040614
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
PRIMARY | |||
|
100000128100
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
PRIMARY | |||
|
SODIUM PYRUVATE
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
PRIMARY | |||
|
SUB34799
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
PRIMARY | |||
|
204-024-4
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
PRIMARY | |||
|
POD38AIF08
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
PRIMARY | |||
|
50144
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
PRIMARY | |||
|
DBSALT001546
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
PRIMARY | |||
|
POD38AIF08
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
PRIMARY | |||
|
1358847
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
PRIMARY | RxNorm | ||
|
23662274
Created by
admin on Mon Mar 31 17:50:10 GMT 2025 , Edited by admin on Mon Mar 31 17:50:10 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |